Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.69 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 6/20 | 0.50 |
| ▸ | PPARD | Q03181 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 6/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL143984 | 0.93 | FFAR3 (0.67) | FFAR3LMNAEGLN1ALKBH5SUCNR1 | |
| Propionic Acid SCHEMBL28056890 | 0.92 | — | — | |
| Succinic Acid SCHEMBL28184121 | 0.88 | LMNA (0.75) | FFAR3LMNAEGLN1ALKBH5SUCNR1 | |
| Propionic Acid SCHEMBL1331656 | 0.88 | — | — | |
| Propionic Acid SCHEMBL1462509 | 0.88 | FFAR3 (1.00) | FFAR3LMNAEGLN1ALKBH5SUCNR1 | |
| Propionic Acid SCHEMBL11661434 | 0.88 | FFAR3 (1.00) | FFAR3LMNAEGLN1ALKBH5SUCNR1 | |
| Propionic Acid SCHEMBL1331605 | 0.88 | — | — | |
| Propionic Acid SCHEMBL7088331 | 0.88 | FFAR3 (1.00) | FFAR3LMNAEGLN1ALKBH5SUCNR1 | |
| Propionic Acid SCHEMBL1332599 | 0.88 | — | — | |
| Propionic Acid SCHEMBL290 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2024-06-27 | — | — | US | claimed |
| CN-117777555-A | Environment-friendly fresh-keeping film with adjustable air permeability and preparation method and application thereof | 上海海洋大学 | 2024-03-29 | — | — | CN | claimed |
| EP-4322933-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA INC. (CA) | 2024-02-21 | — | — | EP | claimed |
| EP-4084778-B1 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-11-01 | — | — | EP | claimed |
| EP-4214183-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | Essa Pharma, Inc. (CA) | 2023-07-26 | — | — | EP | claimed |
| WO-2023044462-A1 | CYSTEINE PROTEASE INHIBITOR FORMULATIONS AND METHOD OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | claimed |
| EP-4084779-A1 | COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREA | Deciphera Pharmaceuticals, LLC (US) | 2022-11-09 | — | — | EP | claimed |
| CN-115135308-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2022-09-30 | — | — | CN | claimed |
| US-20220142969-A1 | WATER-SOLUBLE CANNABINOID FORMULATIONS AND METHODS OF THEIR MAKING | SOLUSCIENCE, LLC | 2022-05-12 | — | — | US | claimed |
| US-20220105093-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMACEUTICALS CORP. (CA) | 2022-04-07 | — | — | US | claimed |
| EP-1401503-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | LONZA BEND INC. | 2003-06-05 | — | — | US | claimed |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003000294-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF A POORLY-SOLUBLE DRUG IN A MATRIX AND A SOLUBILITY-ENHANCING POLYMER | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| WO-2003000238-A1 | PHARMACEUTICAL COMPOSITIONS OF ADSORBATES OF AMORPHOUS DRUG | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-5840329-A | GROUPS OF PARTICLES HAVING DISTINCT PATTERN OF DRUG RELEASE BASED ON COMBINATION OF CONTROLLED RELEASE LAYERS, SWELLING AGENTS AND COATINGS; CONTROLLED RELEASE LAYER OF SLIGHTLY CROSSLINKED POLYACRYLIC ACID AND WATER SOLUBLE POLYMER | BIOADVANCES LLC (US) | 1998-11-24 | — | — | US | claimed |
| WO-1998051287-A1 | PULSATILE DRUG DELIVERY SYSTEM | BAI JANE PEI FAN (US) | 1998-11-19 | — | — | WO | claimed |
| EP-0663202-B1 | Mascara make-up cosmetic compositions containing at least one wax and cellulose derivate pseudo-latex | OREAL (FR) | 1998-07-29 | — | — | EP | claimed |
| US-5747013-A | Makeup cosmetic composition in the form of a mascara containing at least a wax and a pseudo-latex of cellulose derivatives | L'OREAL (FR) | 1998-05-05 | — | — | US | claimed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104063-A1 | Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers | ABCG2, ABCB1, MATR3 | FFAR3 3835/4885LMNA 511/4885EGLN1 3738/4885 |
| US-20030054037-A1 | Pharmaceutical compositions of adsorbates of amorphous drug | ABCG2, ALB, SLCO1A2 | FFAR3 1613/4885LMNA 2542/4885EGLN1 4525/4885 |
| US-20240207264-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, NR5A1, SHBG | FFAR3 222/4885LMNA 3567/4885EGLN1 4074/4885 |
| US-20220105093-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | AR, SHBG, NR3C2 | FFAR3 402/4885LMNA 3834/4885EGLN1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.